Evidence for effects of older glucose-lowering agents on CV risk
A slide lecture program on glucose lowering agents on CV risk, like: metformin, sulphonylureas, TZDs, and a rationale for FDA guidance.
Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME
Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME
To download slides
Download PACE ACROSS T2D Module C_11Aug15.pptx
To view slides click on images
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: